Enveric Biosciences, Inc.
As of Oct 22, 2026, Enveric Biosciences is in Stage 1, the basing phase, now in week 5 (since Sep 18, 2026). It closed at $1.46, 85.9% below its 52-week high and below its 200-day average, which is falling.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ENVB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ENVB among Biotechnology476th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …476 | ENVB | Stage 1 · wk 5 | 10 | −6.7% |
Enveric Biosciences: quick answers
What stage is Enveric Biosciences in?
As of Oct 22, 2026, Enveric Biosciences (ENVB) is in Stage 1, the basing phase. It entered Stage 1 on Sep 18, 2026 and is in week 5. What the four stages mean
Is Enveric Biosciences in an uptrend?
Not yet. Enveric Biosciences is in Stage 1, a base that can come before an uptrend. It trades 30.4% below its 200-day average, which is falling.
How far is Enveric Biosciences from its 52-week high?
Enveric Biosciences closed at $1.46 on Oct 22, 2026, 85.9% below its 52-week high of $10.33. Its 52-week low is $1.27.
How has Enveric Biosciences performed over the past year?
As of Oct 22, 2026, Enveric Biosciences is down 82.1% over the past year and down 60.2% so far in 2026.
Which sector and industry is Enveric Biosciences in?
Enveric Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.